Bechtold, Andrea G., and Deborah A. Scheuer. Glucocorticoids act in the dorsal hindbrain to modulate baroreflex control of heart rate. Am J Physiol Regul Integr Comp Physiol 290: R1003-R1011, 2006. First published November 3, 2005 doi:10.1152/ajpregu.00345.2005.-Systemic corticosterone (Cort) modulates arterial baroreflex control of both heart rate and renal sympathetic nerve activity. Because baroreceptor afferents terminate in the dorsal hindbrain (DHB), an area with dense corticosteroid receptor expression, we tested the hypothesis that prolonged activation of DHB Cort receptors increases the midpoint and reduces the gain of arterial baroreflex control of heart rate in conscious rats. Small (3-4 mg) pellets of Cort (DHB Cort) or Silastic (DHB Sham) were placed on the surface of the DHB, or Cort was administered systemically by placing a Cort pellet on the surface of the dura (Dura Cort). Baroreflex control of heart rate was determined in conscious male Sprague Dawley rats on each of 4 days after initiation of treatment. Plots of arterial pressure vs. heart rate were analyzed using a four-parameter logistic function. After 3 days of treatment, the arterial pressure midpoint for baroreflex control of heart rate was increased in DHB Cort rats (123 Ϯ 2 mmHg) relative to both DHB Sham (108 Ϯ 3 mmHg) and Dura Cort rats (109 Ϯ 2 mmHg, P Ͻ 0.05). On day 4, baseline arterial pressure was greater in DHB Cort (112 Ϯ 2 mmHg) compared with DHB Sham (105 Ϯ 2 mmHg) and Dura Cort animals (106 Ϯ 2 mmHg, P Ͻ 0.05), and the arterial pressure midpoint was significantly greater than mean arterial pressure in the DHB Cort group only. Also on day 4, maximum baroreflex gain was reduced in DHB Cort (2.72 Ϯ 0.12 beats ⅐ min Ϫ1 ⅐ mmHg Ϫ1 ) relative to DHB Sham and Dura Cort rats (3.51 Ϯ 0.28 and 3.37 Ϯ 0.27 beats ⅐ min Ϫ1 ⅐ mmHg Ϫ1 , P Ͻ 0.05). We conclude that Cort acts in the DHB to increase the midpoint and reduce the gain of the heart rate baroreflex function. corticosterone; nucleus of the solitary tract; glucocorticoid receptors; brain; stress ELEVATED GLUCOCORTICOIDS INCREASE the risk for cardiovascular disease (13,20,46,58,59). Accumulating evidence further indicates that altered glucocorticoid activity or sensitivity, even in the absence of elevated plasma glucocorticoid levels, may play a role in the etiology of human essential hypertension, a primary risk factor for cardiovascular disease (27,47,56,57). Altered glucocorticoid activity has also been implicated in the pathogenesis of metabolic syndrome, a condition whose symptoms include obesity, elevated blood pressure, and insulin resistance or diabetes (55). Genetic factors appear to increase sensitivity to the adverse cardiovascular effects of glucocorticoids, since several recently identified polymorphisms of the human glucocorticoid receptor (GR) gene have been linked to hypertension and cardiovascular disease (25,26,34,35). Complementing the data from humans, a glucocorticoid-dependent mechanism of hypertension has been demonstrated in several rat strains, including s...